Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
SYNTHELIS<br />
B<strong>at</strong>iment Biopolis<br />
5 avenue du Grand Sablon<br />
38700 LA TRONCHE - FRANCE<br />
Phone: +33 4 76 54 95 37<br />
Fax: +33 4 76 54 95 36<br />
Email: bruno.tillier@synthelis.fr<br />
Web site: www.synthelis.fr<br />
Contact: Bruno TILLIER<br />
Synthelis SAS is a start-up company providing a solution to a well known challenge<br />
in terms of biotechnological production, namely the development, characteriz<strong>at</strong>ion<br />
and production of customized membrane proteins and associ<strong>at</strong>ed service offerings.<br />
The company is also working on its own R&D programs with a view to developing<br />
innov<strong>at</strong>ive therapeutic and vaccine approaches based on membrane protein carried<br />
into liposomes<br />
TB DRUG BOOST<br />
3 rue du Professeur Laguesse<br />
59000 LILLE - FRANCE<br />
Phone: +33 3 20 96 40 24<br />
Fax: +33 3 20 96 49 07<br />
Web site: www.deprezlab.fr<br />
Anti-infective drug discovery. We have developed a pl<strong>at</strong>form specialized in screening<br />
for bacterial repressor inhibitiors. Our first program has produced several series<br />
specific nanomolar, bioavailable inhibitors of EthR, a myco-bacterial repressor. In vivo,<br />
these compounds boost the activity of ethionamide, a key antibiotic used in TB. Our<br />
series has reached the level of regul<strong>at</strong>ory development. We are seeking a partnership<br />
for the development of these compounds th<strong>at</strong> have a clinical utility in the tre<strong>at</strong>ment of<br />
MDR strains of tuberculosis.<br />
62
Change language